相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: Interim results
Chao Yin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy
Maria A. Gonzalez-Carmona et al.
SCIENTIFIC REPORTS (2022)
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action
Yingyan Xue et al.
EXPERT OPINION ON DRUG DELIVERY (2021)
PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
Yali Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
Christian Moehring et al.
FRONTIERS IN ONCOLOGY (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle et al.
LANCET ONCOLOGY (2021)
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma
Samuel C. Fehling et al.
CANCER LETTERS (2020)
KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Evan Y. Yu et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Biomarker-Guided Development of DNA Repair Inhibitors
James M. Cleary et al.
MOLECULAR CELL (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo et al.
ESMO OPEN (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
Fan Xiong et al.
ONCOTARGETS AND THERAPY (2020)
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
Elizabeth K. Lee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in patients with relapsed gastric cancer.
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2019)
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
Lei Guo et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel et al.
CANCER LETTERS (2019)
Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma
Maria Angeles Gonzalez-Carmona et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
Junghoon Shin et al.
CANCER RESEARCH AND TREATMENT (2019)
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ling Ding et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
Michael Friedlander et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib plus pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)-Results from ROC cohort.
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
Fatima Karzai et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Talia Golan et al.
ONCOLOGIST (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection
Gaya Spolverato et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis
Randa Tao et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Theodore S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
Bob T. Li et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
Response of BRCA1- mutated gallbladder cancer to olaparib: A case report
Yuan Xie et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Intrahepatic Cholangiocarcinoma: expert consensus statement
Sharon M. Weber et al.
HPB (2015)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Metaanalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Charles E. Ray et al.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY (2013)
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success
Thomas J. Vogl et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Shahid A. Khan et al.
JOURNAL OF HEPATOLOGY (2012)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience
Niraj J. Gusani et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2008)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast
EK Latta et al.
MODERN PATHOLOGY (2002)
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998
SD Taylor-Robinson et al.
GUT (2001)
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
T Patel
HEPATOLOGY (2001)
分享论文
